ThursdayApr 24, 2008 5:42 am

Small Cap Voice Featured Client: Kraig Biocraft Laboratories, Inc. (KBLB.OB)

Kraig Biocraft Laboratories, Inc. (KBLB.OB) is a biotechnology company working on developing commercially significant polymers. Their proprietary genetic engineering technology is used to find solutions in material science. Kraig believes that these commercial polymers will have broad applications in the market for high-strength materials. Kraig has obtained the exclusive rights to spider silk gene sequences, and uses this as the core of their technology. Spider silk is recognized as the strongest fiber produced in nature. The company’s only challenge is that there is currently no way to produce these fibers in commercially viable amounts. The company is working with two…

Continue Reading

ThursdayApr 17, 2008 4:50 pm

Kraig Biocraft Laboratories, Inc. (KBLB.OB) Focuses on the $92 Billion Technical Textile Industry

CEO Kim Thompson made the company’s position in the $92 Billion Technical Textile market clear. The industry is projected to mature to $127 billion in 2010. This market consists of high-strength fibers used in composites, ballistic protection, armor and high strength cable, to name a few. Mr. Thompson provides the case in point of DuPont's participation in this market, whose annual sales with Kevlar, Tyvek, and the like is roughly $5.6 billion a year. He pointed out that Kraig's focal point is in this identical marketplace with its development of spider silk-based, high performance fibers. Spider silk is one of…

Continue Reading

ThursdayApr 10, 2008 3:17 pm

Kraig Biocraft Laboratories (KBLB.OB) Advisory Board Member Dr. Malcolm Fraser Named “Inventor” of Pending Provisional Patent Technology

Kraig Biocraft Laboratories, Inc., a biotechnology company focused on the development of commercially significant high performance polymers and technical fiber, announced that a provisional patent application, with groundbreaking technology describing a platform for antigen presentation and antibody test kits, has been filed. The patent lists Dr. Malcolm Fraser of Notre Dame, a member of Kraig’s Scientific Advisory Board, and a scientific consultant to Kraig, as the named inventor. Dr. Malcolm Fraser explains, “The invention describes engineered polymers which incorporate diagnostic antigens. The genetically fused polymers can potentially be fashioned into a number of different diagnostic test platforms including serum (blood),…

Continue Reading

Market Basics

New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

The Basics

Newsletter Publishers

Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

Register

Public Companies

Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

Get Covered